Tempus AI jumps after Merck-Moderna melanoma trial results
Tempus AI shares are rising after Merck and Moderna released Phase 3 INTerpath-001 results for intismeran autogene in resected melanoma, which traders linked to Tempus’s planned Personalis acquisition.
Shares of Tempus AI Inc (NASDAQ: TEM ) are surging Wednesday morning as traders connected the dots between a landmark clinical trial win and Tempus’s recent multi-billion dollar acquisition deal.
Here’s what investors need to know.
Tempus AI stock is surging to new heights today.
What’s behind TEM gains? Landmark mRNA Trial Delivers Breakthrough Results The rally follows Phase 3 trial results released Wednesday morning by Merck & Co Inc and Moderna Inc.
The pharmaceutical partners revealed that their INTerpath-001 trial evaluating intismeran autogene, a custom mRNA-based individualized neoantigen therapy paired with Keytruda, significantly improved recurrence-free survival in resected melanoma patients.
The news represents the first successful Phase 3 readout for a custom mRNA-based cancer treatment.
The Key Connection: Personalis Infrastructure Drives the Vaccine While Merck and Moderna lead the drug development, the underlying engine powering the personalized vaccine is Personalis Inc’s advanced genomic tumor-profiling technology.
Moderna utilizes Personalis’s sequencing platform to analyze each patient’s unique tumor tissue and identify specific neoantigens needed to manufacture custom doses.
That technological link directly benefits Tempus AI, which previously partnered with Personalis to commercialize minimal residual disease tests and agreed to acquire Personalis for $1.5 billion last month.
By acquiring Personalis, Tempus inherits the critical sequencing infrastructure supporting Moderna’s therapeutic program just as it passes its biggest regulatory and clinical milestone to date.
Tempus CEO Eric Lefkofsky highlighted the connection on social media Wednesday, congratulating Moderna and Merck on the Phase 3 victory while noting Tempus’s pride in partnering with Moderna to support the breakthrough program.
Congratulations to @moderna_tx and @Merck on today’s positive Phase 3 results for INTerpath-001, a major milestone for melanoma treatment and the future of more personalized care.
We are proud to partner with Moderna in support of this important program, and we’re excited to see… — Eric Lefkofsky (@lefkofsky) August 19, 2026 TEM Shares Surge Wednesday Morning TEM Price Action: Tempus AI shares were up 17.77% at $58.13 at the time of publication on Wednesday, according to Pro data.
Read Also: Treasury Just Doubled Its Bond Buybacks: What That Can and Can't Fix Image: Shutterstock